Malaysia

Tuberculosis profile
Population 2009 (millions) 27 Incidence (HIV+TB in orange), notifications (black)
(rates per 100 000 population)
Rate
Estimates of burden * 2009 Number (thousands) 150
(per 100 000 pop)
Mortality (excluding HIV) 2.4 (1.8–3.1) 8.6 (6.4–11) 100
Prevalence (incl HIV) 30 (13–48) 109 (47–173)
Incidence (incl HIV) 23 (21–25) 83 (75–90) 50
Incidence (HIV-positive) 2.5 (2.2–2.7) 8.9 (8.1–9.9)
0
Case detection, all forms (%) 76 (70–84)
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008

Case notifications 2009 Prevalence (rate per 100 000 population)

New cases (%) Retreatment cases (%) 400
Smear-positive 9 981 (59) Relapse 420 (36) 300
Smear-negative 4 143 (24) Treatment after failure 21 (2) 200
Smear unknown 453 (3) Treatment after default 192 (16)
Extrapulmonary 2 344 (14) Other 548 (46) 100
0
Other 0 (0)
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008
Total new 16 921 Total retreatment 1 181
Total < 15 years Mortality excluding HIV
(rate per 100 000 population)
Total new and relapse 17 341 (96% of total)
40
Total cases notified 18 102
30
Drug regimens 20
Rifampicin used throughout treatment Yes
10
% of patients treated with fixed-dose combinations (FDCs) 10 0
Paediatric formulations procured No 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008

Treatment success rate 2008 (%) TB/HIV 2009

New smear-positive 78 TB patients with known HIV status 15 192
New smear-negative/extrapulmonary 70 % of TB patients with known HIV status 84
Retreatment 61 TB patients that are HIV-positive 1 644
% of tested TB patients that are HIV-positive 11
Treatment success rate (%) % HIV-positive TB patients started on CPT 10
80 % HIV-positive TB patients started on ART 10
HIV-positive people screened for TB 2 156
40 New smear +
HIV-positive people provided with IPT 0
0 New smear-/extrap
Retreatment CPT (orange) and ART (green) for HIV-positive TB patients (blue)
19 5
19 6
19 7
19 8
20 9
20 0
20 1
20 2
20 3
20 4
20 5
20 6
07
9
9
9
9
9
0
0
0
0
0
0
0
19

2000
MDR-TB, Estimates among notified cases * 2008 1500
% of new TB cases with MDR-TB 0.10 (0.0–0.60) 1000
% of retreatment TB cases with MDR-TB 0.0 (0.0–19)
500
Estimated MDR-TB cases among notified
15 (0–320) 0
pulmonary TB cases 2009
2003 2004 2005 2006 2007 2008 2009

Retreat- Financing 2010 2011

MDR-TB reported cases 2009 New ment Total
Total budget (US$ millions) 4 6
Cases tested for MDR-TB 7 664 Available funding (US$ millions) 4 6
% of notified tested for MDR-TB 42 % of budget funded 100 100
Confirmed cases of MDR-TB 55 % available funding from domestic sources 100 100
MDR-TB patients started treatment 0 % available funding from Global Fund 0 0

NTP Budget (blue) and available funding (green) (US$ millions)

Laboratories 2008 2009 2010 6
Smear (per 100 000 population) 2.4 2.6 2.5
4
Culture (per 5 million population) 2.6 5.8 5.7
DST (per 10 million population) 1.1 1.5 2.1
2
Second-line DST available In country 0
National Reference Laboratory Yes 2006 2007 2008 2009 2010 2011

* Ranges represent uncertainty intervals Generated: January 21, 2011 Source: www.who.int/tb/data